Anna Hercot

CEO at Evariste

Presenter

Evariste advances synthetic lethal oncology using its AI-enabled platform, Frobenius. We identify novel synthetic lethal targets and biomarkers, then address them by developing best-in-class small molecule drug candidates. Our platform has been validated through several external partnerships and our internal pipeline, which includes a best-in-class PKMYT1 inhibitor program addressing a novel biomarker and several first-in-class assets aimed at novel targets.